Vivimed Labs (NSE:VIVIMEDLAB) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
33 GF Score
Price ₹5.71
GF Value ₹2.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs ROE % Adjusted to Book Value?

Vivimed Labs NSE:VIVIMEDLAB -0.87% 33 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 33/100 and a GF Value™ of ₹2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Vivimed Labs's ROE % for the quarter that ended in Dec. 2025 was 0.00%. Vivimed Labs's PB Ratio for the quarter that ended in Dec. 2025 was N/A. Vivimed Labs's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

Vivimed Labs ROE % Adjusted to Book Value Related Terms

Vivimed Labs ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs ROE % Adjusted to Book Value Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.65 -51.52 -117.09 0.00 0.00

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:VIVIMEDLAB vs ZTS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivimed Labs ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vivimed Labs's ROE % Adjusted to Book Value falls into.


NSE:VIVIMEDLAB
33GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs ROE % Adjusted to Book Value Calculation

Vivimed Labs's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Vivimed Labs's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' ROE % Adjusted to Book Value too high?
Vivimed Labs' current ROE % Adjusted to Book Value is 0.00%. Overall, Vivimed Labs has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' ROE % Adjusted to Book Value compare to ZTS?
Vivimed Labs' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.53, compared to a current price of ₹5.71 — trading 125.7% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Vivimed Labs' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.71 is trading 125.7% above its estimated GF Value™ of ₹2.53. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • ROE % Adjusted to Book Value: 0.00%
  • GF Value™: ₹2.53 vs. price of ₹5.71 (125.7% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
33GF Score

Get the complete analysis for NSE:VIVIMEDLAB

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.71
Price
₹2.53
GF Value